Expanding Our Pipeline with Industry-Leading Partners
Our current strategic collaborations are focused on discovering and developing innovative therapies using our DELigase platform. Each collaboration addresses a unique set of targets chosen by our partner, is distinct from our proprietary pipeline, and employs our DELigase platform and Targeted Protein Degradation.
Gilead Sciences
In June 2019, Nurix entered into a global strategic collaboration with Gilead to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. Read More
In March 2023, Gilead and Nurix announced that Gilead exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule, NX-0479, a potent, selective, oral degrader of IRAK4. IRAK4 degradation has potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases. In connection with the option exercise, Nurix received a payment of $20 million. Read More
In April 2024, Nurix announced the extension of its strategic collaboration with Gilead Sciences, increasing the research term by two years with the intention to generate multiple additional clinical candidates. In connection with the extension, Nurix received a payment of $15 million. Read More
Sanofi
In January 2020, Nurix entered into a global strategic collaboration with Sanofi to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases. Read More
In January 2021, Nurix announced the expansion of its strategic collaboration with Sanofi, increasing the number of targets from three to a total of five. In connection with the expansion, Nurix received a payment of $22 million, in addition to the initial payment of $55 million. Read More
In April 2024, Nurix announced the extension of its strategic collaboration with Sanofi to develop novel targeted protein degraders of STAT6 (signal transducer and activator of transcription 6). STAT6 is a key drug target in type 2 inflammation. Read More
Pfizer
In September 2023, Nurix announced a strategic collaboration with Seagen (now part of Pfizer), combining industry leading technologies of targeted protein degradation and antibody drug conjugation to advance an innovative new class of cancer therapeutics. Read More